Tamsulosin
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Omnick has an alpha-adrenolytic effect.
Pharmacodynamics
Blockade α1-adrenoreceptors tamsulosin leads to a decrease in the tone of the smooth muscles of the prostate gland, bladder neck and prostatic urethra and improve urine flow. At the same time, both emptying symptoms and filling symptoms due to increased smooth muscle tone and detrusor hyperactivity in benign prostatic hyperplasia decrease.
The ability of tamsulosin to affect α1A- subtype of adrenoreceptors is 20 times greater than its ability to interact with α1B-subtype of adrenoreceptors, which are located in the smooth muscles of blood vessels. Due to its high selectivity, tamsulosin does not cause a clinically significant reduction in systemic blood pressure in patients with arterial hypertension, and in patients with normal baseline blood pressure.
Pharmacokinetics
Suction
Tamsulosin is well absorbed in the intestines and has almost 100% bioavailability. Tamsulosin absorption slows down somewhat after eating. The same level of absorption can be achieved if the patient takes the drug each time after a normal breakfast. Tamsulosin is characterized by linear kinetics. After a single dose of 0.4 mg of its drug Cmax in plasma is reached after 6 hours. After repeated ingestion of 0.4 mg per day, the equilibrium concentration is reached by the 5th day, while its value is about 2/3 higher than the value of this parameter after taking a single dose.
Distribution
Plasma protein binding is 99%, the volume of distribution is small (about 0.2 l / kg).
Metabolism
Tamsulosin is slowly metabolized in the liver to form less active metabolites. Most tamsulosin is unchanged in blood plasma.
The experiment revealed the ability of tamsulosin to slightly induce the activity of microsomal liver enzymes.
With an insignificant and moderate degree of liver failure, no correction of the dosing regimen is required.
Removal
Tamsulosin and its metabolites are mainly excreted in the urine, while about 9% of the drug is excreted unchanged.
T1/2 the drug with a single dose of 0.4 mg after a meal is 10 hours, with multiple - 13 hours
In case of renal insufficiency, a dose reduction is not required if the patient has severe renal insufficiency.
Indications
Dysuric disorders in benign prostatic hyperplasia (treatment).
Composition
active substance: tamsulosin hydrochloride 0.4 mg;
Excipients: MCC; methacrylic acid copolymer (type C); polysorbate 80; sodium lauryl sulfate; triacetin; calcium stearate; talc; gelatin; indigotin; titanium dioxide; iron oxide yellow; iron oxide red
Tamsulosin is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Omnic | Astellas | Netherlands | capsules |
Tamsulosin | Vertex | Russia | capsules |
Tamsulosin-OBL | capsules | ||
Proflosin | Berlin-Chemie/Menarini | Germany | capsules |
Tamsulosin | Obolensky OP | Russia | pills |
Tamzelin | Velpharm | Russia | capsules |
Omsulozin | Ranbaxy Laboratories Ltd | India | capsules |
Fokusin | Zentiva KS | Czech | capsules |
Sonizin | Gedeon Richter | Hungary | capsules |
Omnic Ocas | Astellas | Netherlands | pills |
No customer reviews for the moment.
Dosage and Administration
Inside After breakfast, drinking water, 1 capsule (0.4 mg) 1 time per day. Capsule is not recommended to chew, because this may affect the rate of release of the drug.
Adverse reactions
Seldom- dizziness, retrograde ejaculation; in rare cases - orthostatic hypotension, tachycardia / palpitations, asthenia, headache.
From the digestive tract: rarely - nausea, vomiting, diarrhea, constipation.
In extremely rare cases, hypersensitivity reactions (skin rash, itching, angioedema) may occur.
Carefully - severe renal failure
Drug interactions
When prescribing the drug Omnic® no interactions were found with atenolol, enalapril or nifedipine. At simultaneous use of Omnic® with cimetidine, there was a slight increase in the concentration of tamsulosin in the blood plasma, and with furosemide, a decrease in the concentration (this does not require changing the dose of Omnick®because the concentration of the drug remains within the normal range).
Diazepam, propranolol, trichloromethiazide, chlormadinone, amitriptyline, diclofenac, glibenclamide, simvastatin and warfarin do not change the free fraction of tamsulosin in human plasmain vitro. In turn, tamsulosin also does not change the free fractions of diazepam, propranolol, trichloromethiazide and chlormadinone.
In researchin vitro no interaction at the level of hepatic metabolism with amitriptyline, salbutamol, glibenclamide, and finasteride was detected.
Diclofenac and warfarin may increase the rate of elimination of tamsulosin.
Simultaneous administration of other α antagonists1-adrenoretseptorov can lead to lower blood pressure.
Special instructions
As with other α1-blockers, in the treatment of the drug Omnic® in some cases, there may be a decrease in blood pressure, which can sometimes lead to fainting. At the first sign of orthostatic hypotension (dizziness, weakness), the patient should sit down or lie down and remain in that position until the signs disappear. During surgery for cataracts during the administration of the drug, the syndrome of intraoperative instability of the iris of the eye (narrow pupil syndrome) may develop, which must be considered by the surgeon for the preoperative preparation of the patient and during the operation.
Before starting therapy with Omnick®, the patient should be examined in order to exclude the presence of other diseases that can cause the same symptoms as benign prostatic hyperplasia. Before treatment, and regularly during therapy, a digital rectal examination should be performed and, if required, the determination of prostate specific antigen (PSA).
Overdosage
Symptoms: acute hypotension.
Treatment: to prevent further absorption of the drug, it is advisable to wash the stomach, to appoint the reception of Activated charcoal and osmotic laxative, for example, sodium sulfate; Blood pressure and heart rate can recover if the patient is placed in a horizontal position. In the absence of effect, it is possible to use agents that increase the bcc and, if necessary, vasoconstrictor agents. Kidney function should be monitored. It is unlikely that dialysis will be effective, as tamsulosin is intensively bound to plasma proteins.
- Active ingredient: Tamsulosin
Studies and clinical trials of Tamsulosin (Click to expand)
- Pharmacology of tamsulosin: Saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes
- Rapid, simple and highly sensitive LC-ESI-MS/MS method for the quantification of tamsulosin in human plasma
- Quantification of pramipexole in human plasma by liquid chromatography tandem mass spectrometry using tamsulosin as internal standard
- ChemInform Abstract: Asymmetric Formal Synthesis of (-)-Formoterol and (-)-Tamsulosin.
- ChemInform Abstract: Improved Process for the Preparation of Tamsulosin Hydrochloride.
- New practical synthesis of Tamsulosin
- Simultaneous contactless conductivity detection and UV detection for the study of separation of tamsulosin enantiomers in discontinuous electrolyte systems by CE
- The effect of tamsulosin on the response of the rabbit bladder to partial outlet obstruction
- Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia
- Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency–volume chart
- Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology
- Evaluating tamsulosin hydrochloride-released microparticles prepared using single-step matrix coating
- The role of prophylactic Tamsulosin ± dexamethasone in patients undergoing prostate 125I seed implants for prostate carcinoma. A randomized double-blind study
- Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study
- Does the Addition of Tamsulosin to Outpatient Analgesic Therapy Enhance Spontaneous Stone Passage in Patients With Uncomplicated Distal Ureteral Stones?
- Tamsulosin for Ureteral Stones in the Emergency Department: A Randomized, Controlled Trial
- Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues
- Determination of tamsulosin in dog plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry
- Rapid determination of tamsulosin in human plasma by high-performance liquid chromatography using extraction with butyl acetate
- Chiral separation of tamsulosin by capillary electrophoresis
- Development of a validated RP-LC/ESI-MS–MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations
- The role of prophylactic tamsulosin (Flomax) in patients undergoing prostate 125-I seed implants for prostate carcinoma: final report of double-blind placebo-controlled randomized study